MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
MindMaze Therapeutics has announced its 2026 half-year results, highlighting progress in commercial capabilities and a commitment to executing their strategy. The CEO emphasized the company’s potential in scalable neurotherapeutics backed by robust clinical evidence and an expanding market presence, particularly in the United States.
GENEVA, Aug. 27, 2026 /PRNewswire/ — MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update. Key Highlights…